维格列汀及阿卡波糖对老年糖尿病患者不良反应的影响(1)
[摘要] 目的 观察维格列汀及阿卡波糖对老年糖尿病患者不良反应的影响临床效果。 方法 采用临床资料查证法，选取该院2015—2016年收治的128例老年糖尿病患者，按照治疗药物配伍方法的不同，随机分为对照组和研究组，随机平均分成两组。对照组患者应用单独维格列汀方法治疗，观察组在此基础上增加阿卡波糖的联合治疗策略，比较两组患者的临床疗效。结果 从血糖整体控制水平来看，观察组明显优于对照组，两组数据差异有统计学(P<0.05)；观察组的血清C肽(空腹血清C肽和餐后2h C肽)整体控制水平明显优于对照组，两组数据差异有统计学意义(P<0.05)。结论 维格列汀及阿卡波糖对老年糖尿病患者不良反应的影响临床效果确切，具有较高的血糖控制和调节力，并在临床护理实践中得到了一些研究学者的证实，值得临床推广应用。
[关键词] 维格列汀；阿卡波糖；老年糖尿病；不良反应
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2018)02(a)-0062-02
Effect of Vildagliptin Combined with Acarbose on the Adverse Reactions of Senile Diabetes Patients
GE Yan-ping， ZHANG Hong-xia
Department of Internal Medicine， Daqing Oil Chengfeng Hospital， Daqing， Heilongjiang Province， 163411 China
[Abstract] Objective To observe the clinical effect of vildagliptin combined with acarbose on the adverse reactions of senile diabetes patients. Methods 128 cases of senile diabetic patients admitted and treated in our hospital from 2015 to 2016 were selected and randomly divided into two groups， the control group applied the single vildagliptin， while the observation group were treated with vildagliptin combined with acarbose， and the clinical curative effect was compared between the two groups. Results The blood glucose holistic control level in the observation group was obviously better than that in the control group， and the difference was statistically significant(P<0.05)， and the serum C peptide (fasting serum C peptide and postprandial 2h C peptide holistic control levels were obviously better than those in the control group， and the differences between the two groups were statistically significant(P<0.05). Conclusion The effect of vildagliptin combined with acarbose on the adverse reactions of senile diabetes patients is definite， with higher blood glucose control and adjustment force， and it can be confirmed in the clinical nursing practice， and it is worth clinical promotion and application.
[Key words] Vildagliptin； Acarbose； Senile diabetes； Adverse reaction
糖尿病(Diabetes)是老年常見病、多发病，以60岁以上老年人最为常见。老年患者多为继发性因素影响，该疾病属代谢类内分泌循环系统疾病，有着较高的致残率和病死率。糖尿病患者的不良反应以血糖的起伏波动而引起系列病程，常给患者的预后健康带来极大的不便。维格列汀和阿卡波糖作为口服降糖药物，在控制年糖尿病患者上，发挥了自身的独特优势，尽管如此，单独治疗与联合治疗的探讨，成为研究领域的热点。2015—2016年该研究循证两种治疗药物现状，选用合适的治疗方法，取得了相应的治疗成果，现报道如下。
1 资料与方法
1.1 一般资料
采用临床资料查证法，选取该院收治的128例老年糖尿病患者，按照治疗药物配伍方法的不同，随机分为对照组和研究组，随机平均分成两组。对照组：男38例，女26例(共计64例)，年龄60～82岁，平均年龄(70±0.65)岁；观察组：男39例，女25例(共计64例)，年龄62～80岁，平均年龄(70±0.65)岁.两组患者的临床资料差异无统计学意义(P>0.05)。, http://www.100md.com(葛艳平 张红霞)
[关键词] 维格列汀；阿卡波糖；老年糖尿病；不良反应
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2018)02(a)-0062-02
Effect of Vildagliptin Combined with Acarbose on the Adverse Reactions of Senile Diabetes Patients
GE Yan-ping， ZHANG Hong-xia
Department of Internal Medicine， Daqing Oil Chengfeng Hospital， Daqing， Heilongjiang Province， 163411 China
[Abstract] Objective To observe the clinical effect of vildagliptin combined with acarbose on the adverse reactions of senile diabetes patients. Methods 128 cases of senile diabetic patients admitted and treated in our hospital from 2015 to 2016 were selected and randomly divided into two groups， the control group applied the single vildagliptin， while the observation group were treated with vildagliptin combined with acarbose， and the clinical curative effect was compared between the two groups. Results The blood glucose holistic control level in the observation group was obviously better than that in the control group， and the difference was statistically significant(P<0.05)， and the serum C peptide (fasting serum C peptide and postprandial 2h C peptide holistic control levels were obviously better than those in the control group， and the differences between the two groups were statistically significant(P<0.05). Conclusion The effect of vildagliptin combined with acarbose on the adverse reactions of senile diabetes patients is definite， with higher blood glucose control and adjustment force， and it can be confirmed in the clinical nursing practice， and it is worth clinical promotion and application.
[Key words] Vildagliptin； Acarbose； Senile diabetes； Adverse reaction
糖尿病(Diabetes)是老年常見病、多发病，以60岁以上老年人最为常见。老年患者多为继发性因素影响，该疾病属代谢类内分泌循环系统疾病，有着较高的致残率和病死率。糖尿病患者的不良反应以血糖的起伏波动而引起系列病程，常给患者的预后健康带来极大的不便。维格列汀和阿卡波糖作为口服降糖药物，在控制年糖尿病患者上，发挥了自身的独特优势，尽管如此，单独治疗与联合治疗的探讨，成为研究领域的热点。2015—2016年该研究循证两种治疗药物现状，选用合适的治疗方法，取得了相应的治疗成果，现报道如下。
1 资料与方法
1.1 一般资料
采用临床资料查证法，选取该院收治的128例老年糖尿病患者，按照治疗药物配伍方法的不同，随机分为对照组和研究组，随机平均分成两组。对照组：男38例，女26例(共计64例)，年龄60～82岁，平均年龄(70±0.65)岁；观察组：男39例，女25例(共计64例)，年龄62～80岁，平均年龄(70±0.65)岁.两组患者的临床资料差异无统计学意义(P>0.05)。, http://www.100md.com(葛艳平 张红霞)